Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cendakimab · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Cendakimab | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Administration of Cendakimab and Cytochrome P450 (CYP) substrates | EXPERIMENTAL | - |
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cendakimab | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on specified days |
| CYP substrates | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants must be Chinese (both biological parents are ethnically Chinese). * Body mass index (BMI) of 18.0 through 28.0 kilograms/meter squared (kg/m\^2), inclusive. BMI = weight (kg)/\[height (m)\]\^2. * Body weight ≥ 50.0 kg. Exclusion Criteria: * History of clinically...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tezepelumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | dupilumab |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | PHASE2 | Vonoprazan |
| Eupraxia Pharmaceuticals, Inc. | EPRX | 1 | PHASE1 | EP-104GI |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Dupilumab |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | - | Undisclosed |
Cendakimab is an investigational small molecule being studied for gastrointestinal conditions, specifically eosinophilic esophagitis. It has also been evaluated in healthy participants and healthy volunteers in early-stage clinical trials. The drug is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development.
Cendakimab is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting Phase 1 clinical trials to evaluate the drug in healthy participants and in adults with eosinophilic esophagitis.
Cendakimab is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed in healthy volunteers and in participants with eosinophilic esophagitis.
Cendakimab has been studied in three completed Phase 1 trials. NCT05175352 evaluated potential drug-drug interactions in adults with eosinophilic esophagitis. NCT05337345 assessed drug levels after subcutaneous delivery in healthy participants. NCT05638282 evaluated safety and tolerability in Chinese healthy participants.
Yes, Cendakimab is a small molecule therapeutic. It is being developed for gastrointestinal indications, with clinical trials focusing on eosinophilic esophagitis and healthy volunteer studies. The drug is administered subcutaneously, as indicated in one of its clinical trials.